Stevens Capital Management’s Myriad Genetics MYGN Stock Holding History

Stevens Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-11,529	Closed	-$353K	–	1054
2016 Q2	$353K	Buy	+11,529	New	+$401K	0.01%	654
2014 Q1	–	Sell	-11,914	Closed	-$250K	–	1237
2013 Q4	$250K	Sell	11,914 -1,431	-11%	-$36.2K	0.01%	851
2013 Q3	$314K	Buy	+13,345	New	+$379K	0.01%	771

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Stevens Capital Management's MYGN Position: Q3 2016 in Review

Stevens Capital Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 11,529 shares — an estimated $353K sold.

Stevens Capital Management first reported a position in MYGN in Q3 2013 and held it in 3 quarters. The position peaked at $353K in Q2 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Stevens Capital Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Stevens Capital Management sold 11,529 Myriad Genetics shares in Q3 2016, an estimated $353K.
Stevens Capital Management first reported a position in Myriad Genetics in Q3 2013 and held it in 3 quarters.
Stevens Capital Management's Myriad Genetics position peaked at $353K in Q2 2016.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Stevens Capital Management's 13F filing for Q3 2016, filed 8 Nov 2016.